Navigation Links
Cleveland Clinic researchers discover process that turns 'good cholesterol' bad
Date:1/26/2014

Cleveland: Cleveland Clinic researchers have discovered the process by which high-density lipoprotein (HDL) the so-called "good cholesterol" becomes dysfunctional, loses its cardio-protective properties, and instead promotes inflammation and atherosclerosis, or the clogging and hardening of the arteries. Their research was published online today in the journal Nature Medicine.

The beneficial and cardio-protective properties of HDL have been studied and reported extensively, yet all clinical trials of pharmaceuticals designed to raise HDL levels have so far failed to show that they significantly improve cardiovascular health. This disconnect, as well as recent research showing that a protein abundant in HDL is present in an oxidized form in diseased artery walls, spurred the research team led by Stanley Hazen, M.D., Ph.D., Vice Chair of Translational Research for the Lerner Research Institute and section head of Preventive Cardiology & Rehabilitation in the Miller Family Heart and Vascular Institute at Cleveland Clinic to study the process by which HDL becomes dysfunctional.

Apolipoprotein A1 (apoA1) is the primary protein present in HDL, providing the structure of the molecule that allows it to transfer cholesterol out of the artery wall and deliver it to the liver, from which cholesterol is excreted. It's apoA1 that normally gives HDL its cardio-protective qualities, but Dr. Hazen and his colleagues have discovered that in the artery wall during atherosclerosis, a large proportion of apoA1 becomes oxidized and no longer contributes to cardiovascular health, but rather, contributes to the development of coronary artery disease.

Over the course of more than five years, Dr. Hazen and his colleagues developed a method for identifying dysfunctional apoA1/HDL and discovered the process by which it is oxidized and turned dysfunctional in the artery wall. They then tested the blood of 627 Cleveland Clinic cardiology patients for the dysfunctional HDL and found that higher levels raised the patient's risk for cardiovascular disease.

"Identifying the structure of dysfunctional apoA1 and the process by which it becomes disease-promoting instead of disease-preventing is the first step in creating new tests and treatments for cardiovascular disease," said Dr. Hazen. "Now that we know what this dysfunctional protein looks like, we are developing a clinical test to measure its levels in the bloodstream, which will be a valuable tool for both assessing cardiovascular disease risk in patients and for guiding development of HDL-targeted therapies to prevent disease."

The research also points toward new therapeutic targets for pharmaceuticals, such as those designed to prevent the formation of dysfunctional HDL and the development or progression of atherosclerosis.


'/>"/>

Contact: Laura Ambro
ambrol@ccf.org
216-636-5876
Cleveland Clinic
Source:Eurekalert

Related biology news :

1. Cleveland Clinic identifies mechanism in Alzheimers-related memory loss
2. 2 Cleveland Clinic researchers honored for contribution to science
3. Cleveland Clinics 2013 Obesity Summit explores causes, prevention and treatment of obesity
4. Cleveland Clinic research shows gut bacteria byproduct predicts heart attack and stroke
5. Cleveland Clinic researchers discover new link between heart disease and red meat
6. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
7. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
8. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
9. Complimentary press registration now open for ACMG 2014 Annual Clinical Genetics Meeting
10. Case Western Reserve wins $12.7 million for AIDS research and clinical trials
11. MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... ... October 11, 2019 , ... Advanced Clinical, ... researcher Dr. Pavel Tyan has been appointed Therapeutic Lead for Oncology. Dr. Tyan ... enhancing the already strong scientific and delivery credentials previously offered at Advanced Clinical. ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... the National Research Council of Canada (NRC) to create the Laboratory of ... technologies and in manufacturing, LIFT will offer a competitive capacity to accelerate ...
(Date:10/4/2019)... ... 04, 2019 , ... Representatives with MyBioGate ( https://events.mybiogate.com/ ) ... Elysée Hamburg Rothenbaumchaussee in Hamburg. , “To better connect Chinese companies and European ... President of Operations and spokesperson for MyBioGate. , Guo went on to highlight ...
Breaking Biology News(10 mins):
(Date:9/24/2019)... ... 24, 2019 , ... Personalized Stem Cells, Inc ... for clinical trial sites and physician investigators. The clinical trial sites are ... , Clinical trial sites are currently located in San Diego and Los Angeles ...
(Date:9/17/2019)... SOMERSET, N.J. (PRWEB) , ... September 17, 2019 ... ... today announced that Julie Delaney, Director, Project and Clinical Supplies Management, Asia Pacific ... at the One Farrer Hotel, Singapore, on Sept. 25-26, 2019. , On Thursday, ...
(Date:9/17/2019)... , ... September 16, 2019 , ... When a lot ... kits that allow for the complete 3D characterization of tissues through the use of ... into an imaging, image analysis and advanced cell culture focused contract research organization and ...
(Date:9/11/2019)... ... September 09, 2019 , ... Suvoda LLC , ... drug supply chain management, today announced its new technology partnership with Veeva ... “The integration between Veeva Vault EDC and our IRT will enable sponsors and ...
Breaking Biology Technology: